{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:46:24Z","timestamp":1781786784761,"version":"3.54.5"},"reference-count":68,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004221","name":"Pedagogical University of Krakow","doi-asserted-by":"publisher","award":["BN.711-56\/PBU\/2021"],"award-info":[{"award-number":["BN.711-56\/PBU\/2021"]}],"id":[{"id":"10.13039\/501100004221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004221","name":"Pedagogical University of Krakow","doi-asserted-by":"publisher","award":["N42\/DBS\/000331"],"award-info":[{"award-number":["N42\/DBS\/000331"]}],"id":[{"id":"10.13039\/501100004221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004221","name":"Pedagogical University of Krakow","doi-asserted-by":"publisher","award":["N42\/DBS\/000330"],"award-info":[{"award-number":["N42\/DBS\/000330"]}],"id":[{"id":"10.13039\/501100004221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007088","name":"Jagiellonian University","doi-asserted-by":"publisher","award":["BN.711-56\/PBU\/2021"],"award-info":[{"award-number":["BN.711-56\/PBU\/2021"]}],"id":[{"id":"10.13039\/501100007088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007088","name":"Jagiellonian University","doi-asserted-by":"publisher","award":["N42\/DBS\/000331"],"award-info":[{"award-number":["N42\/DBS\/000331"]}],"id":[{"id":"10.13039\/501100007088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007088","name":"Jagiellonian University","doi-asserted-by":"publisher","award":["N42\/DBS\/000330"],"award-info":[{"award-number":["N42\/DBS\/000330"]}],"id":[{"id":"10.13039\/501100007088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In order to find new hypotensive drugs possessing higher activity and better selectivity, a new series of fifteen 5,5-dimethylhydantoin derivatives (1\u201315) was designed. Three-step syntheses, consisting of N-alkylations using standard procedures as well as microwaves, were carried out. Crystal structures were determined for compounds 7\u20139. All of the synthesized 5,5-dimethylhydantoins were tested for their affinity to \u03b11-adrenergic receptors (\u03b11-AR) using both in vitro and in silico methods. Most of them displayed higher affinity (Ki &lt; 127.9 nM) to \u03b11-adrenoceptor than urapidil in radioligand binding assay. Docking to two subtypes of adrenergic receptors, \u03b11A and \u03b11B, was conducted. Selected compounds were tested for their activity towards two \u03b11-AR subtypes. All of them showed intrinsic antagonistic activity. Moreover, for two compounds (1 and 5), which possess o-methoxyphenylpiperazine fragments, strong activity (IC50 &lt; 100 nM) was observed. Some representatives (3 and 5), which contain alkyl linker, proved selectivity towards \u03b11A-AR, while two compounds with 2-hydroxypropyl linker (11 and 13) to \u03b11B-AR. Finally, hypotensive activity was examined in rats. The most active compound (5) proved not only a lower effective dose than urapidil but also a stronger effect than prazosin.<\/jats:p>","DOI":"10.3390\/ijms242316609","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T04:21:27Z","timestamp":1700626887000},"page":"16609","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Subtype Selectivity in Search of Potent Hypotensive Agents among 5,5-Dimethylhydantoin Derived \u03b11-Adrenoceptors Antagonists"],"prefix":"10.3390","volume":"24","author":[{"given":"Aneta","family":"Kaczor","sequence":"first","affiliation":[{"name":"Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Knutelska","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4408-9804","authenticated-orcid":false,"given":"Katarzyna","family":"Kucwaj-Brysz","sequence":"additional","affiliation":[{"name":"Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Zygmunt","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-9370","authenticated-orcid":false,"given":"Ewa","family":"\u017bes\u0142awska","sequence":"additional","affiliation":[{"name":"Institute of Biology and Earth Sciences, University of the National Education Commision, Podchor\u0105\u017cych 2, 30-084 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Siwek","sequence":"additional","affiliation":[{"name":"Department of Pharmacobiology, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Bednarski","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-5603","authenticated-orcid":false,"given":"Sabina","family":"Podlewska","sequence":"additional","affiliation":[{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Medicinal Chemistry, Sm\u0119tna 12, 31-343 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-1214","authenticated-orcid":false,"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Nitek","sequence":"additional","affiliation":[{"name":"Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Sapa","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-3581","authenticated-orcid":false,"given":"Jadwiga","family":"Handzlik","sequence":"additional","affiliation":[{"name":"Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00018-009-0174-4","article-title":"Subtypes of functional alpha1-adrenoceptor","volume":"67","author":"Docherty","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/phrs.2001.0857","article-title":"Alpha-adrenoceptor subtypes","volume":"44","year":"2001","journal-title":"Pharmacol. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1524-6175.2005.05300.x","article-title":"Alpha1-adrenergic blockers: Current usage considerations","volume":"7","author":"Sica","year":"2005","journal-title":"J. Clin. Hypertens."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.bmc.2008.02.091","article-title":"Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents","volume":"16","author":"Jain","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/HJH.0b013e32833b912c","article-title":"Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?","volume":"28","author":"Chapman","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MOU.0b013e32834d9bfd","article-title":"\u03b1-Blockers for benign prostatic hyperplasia: The new era","volume":"22","author":"Lepor","year":"2012","journal-title":"Curr. Opin. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1757-5672.2010.00072.x","article-title":"Clinical Efficacy of \u03b11-Adrenargic Receptor Antagonist Naftopidil 75 mg\/day in Patients with Benign Prostatic Hyperplasia","volume":"2","author":"Kadekawa","year":"2010","journal-title":"Low. Urin. Tract Symptoms"},{"key":"ref_9","first-page":"148","article-title":"Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH-a double-blind randomized trial","volume":"70","author":"Manohar","year":"2017","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.100.23.2336","article-title":"Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age","volume":"100","author":"Rudner","year":"1999","journal-title":"Circulation"},{"key":"ref_11","first-page":"366","article-title":"Genetic variation in the alpha1B-adrenergic receptor and vascular response","volume":"17","author":"Adefurin","year":"2017","journal-title":"Pharm. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1994.tb17053.x","article-title":"Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery","volume":"113","author":"Hatano","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1254\/jjp.80.209","article-title":"A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors","volume":"80","author":"Harada","year":"1999","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00210-010-0558-x","article-title":"Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells","volume":"382","author":"Jensen","year":"2010","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.biopha.2017.01.061","article-title":"Changes in the expression of \u03b11B-adrenoceptor in peripheral mononuclear cells correlates with blood pressure and plasmatic homocysteine","volume":"88","author":"Oliver","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1751-7176.2011.00510.x","article-title":"Alpha 1 adrenoreceptor antagonists","volume":"13","author":"Grimm","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/00005344-200306000-00006","article-title":"Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension","volume":"41","author":"Black","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12325-010-0039-0","article-title":"Urapidil, a dual-acting antihypertensive agent: Current usage considerations","volume":"27","author":"Buch","year":"2010","journal-title":"Adv. Ther."},{"key":"ref_19","first-page":"490","article-title":"Alpha 1-blockade for the treatment of hypertension: A megastudy of terazosin in 2214 clinical practice settings","volume":"16","author":"Itskovitz","year":"1994","journal-title":"Clin. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0002-8703(96)90181-7","article-title":"Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension","volume":"131","author":"Levy","year":"1996","journal-title":"Am. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1586\/14779072.5.6.1027","article-title":"Doxazosin in metabolically complicated hypertension","volume":"5","author":"Penno","year":"2007","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/0002-8703(91)90438-N","article-title":"Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group","volume":"121","author":"Lehtonen","year":"1991","journal-title":"Am. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ajh\/7.5.416","article-title":"Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus","volume":"7","author":"Maheux","year":"1994","journal-title":"Am. J. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.1996.03530440029033","article-title":"Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group","volume":"275","author":"Grimm","year":"1996","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0895-7061(01)02141-0","article-title":"Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients","volume":"14","author":"Hirano","year":"2001","journal-title":"Am. J. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0895-7061(00)01263-2","article-title":"Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL","volume":"14","author":"Kinoshita","year":"2001","journal-title":"Am. J. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00044011-200626090-00006","article-title":"Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance","volume":"26","author":"Derosa","year":"2006","journal-title":"Clin. Drug Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jchf.2018.06.015","article-title":"Safety of Alpha-Adrenergic Receptor Antagonists in Heart Failure","volume":"6","author":"Jackevicius","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/10799893.2010.550008","article-title":"Cardiac and neuroprotection regulated by \u03b1(1)-adrenergic receptor subtypes","volume":"31","author":"Perez","year":"2011","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ahj.2006.05.017","article-title":"Effect of alpha1-adrenergic receptors in cardiac pathophysiology","volume":"152","author":"Shannon","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1161\/01.CIR.83.6.2076","article-title":"Abnormal automatic rhythms in ischemic Purkinje fibers are modulated by a specific alpha 1-adrenergic receptor subtype","volume":"83","author":"Anyukhovsky","year":"1991","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0014-2999(95)00562-5","article-title":"Chloroethylclonidine increases the incidence of lethal arrhythmias during coronary occlusion in anesthetized dogs","volume":"294","author":"Geller","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00944798","article-title":"Effects of selective alpha 1A-adrenoceptor antagonists on reperfusion arrhythmias in isolated rat hearts","volume":"147","author":"Yasutake","year":"1995","journal-title":"Mol. Cell. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Suita, K., Fujita, T., Hasegawa, N., Cai, W., Jin, H., Hidaka, Y., Prajapati, R., Umemura, M., Yokoyama, U., and Sato, M. (2015). Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through \u03b21- and \u03b11-Adrenergic Receptor-Mediated Signaling in Mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133664"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1745-7254.2007.00605.x","article-title":"Receptor subtype involved in alpha 1-adrenergic receptor-mediated Ca2+ signaling in cardiomyocytes","volume":"28","author":"Luo","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_36","first-page":"222","article-title":"Exacerbation of reperfusion arrhythmias by alpha 1 adrenergic stimulation: A potential role for receptor mediated activation of sarcolemmal sodium-hydrogen exchange","volume":"29","author":"Yasutake","year":"1995","journal-title":"Cardiovasc. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1517\/14728222.2011.641534","article-title":"Advances in the design and synthesis of prazosin derivatives over the last ten years","volume":"15","author":"Desiniotis","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jch.14556","article-title":"Role of \u03b11-blockers in the current management of hypertension","volume":"24","author":"Li","year":"2022","journal-title":"J. Clin. Hypertens."},{"key":"ref_39","first-page":"733","article-title":"Synthesis, alpha-adrenoceptors affinity and alpha 1-adrenoceptor antagonistic properties of some 1,4-substituted piperazine derivatives","volume":"66","author":"Marona","year":"2011","journal-title":"Pharmazie"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wu, Y., Zeng, L., and Zhao, S. (2021). Ligands of Adrenergic Receptors: A Structural Point of View. Biomolecules, 11.","DOI":"10.3390\/biom11070936"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.bmc.2012.02.009","article-title":"Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with \u03b11-adrenoceptor affinities","volume":"20","author":"Handzlik","year":"2012","journal-title":"Bioorganic Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1016\/j.bmcl.2016.09.037","article-title":"Synthesis and activity of newly designed aroxyalkyl or aroxyethoxyethyl derivatives of piperazine on the cardiovascular and the central nervous systems","volume":"26","author":"Waszkielewicz","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2016.03.012","article-title":"The effect of urapidil, an alpha-1 adrenoceptor antagonist and a 5-HT1A agonist, on the vascular tone of the porcine coronary and pulmonary arteries, the rat aorta and the human pulmonary artery","volume":"779","author":"Bopp","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/TCRM.S13883","article-title":"Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia","volume":"7","author":"Masumori","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1016\/j.bmc.2008.04.058","article-title":"Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin","volume":"16","author":"Handzlik","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1016\/j.bmcl.2010.07.101","article-title":"Search for influence of spatial properties on affinity at \u03b11-adrenoceptor subtypes for phenylpiperazine derivatives of phenytoin","volume":"20","author":"Handzlik","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1016\/j.bmc.2012.05.064","article-title":"Synthesis and SAR-study for novel arylpiperazine derivatives of 5-arylidenehydantoin with \u03b11-adrenoceptor antagonistic properties","volume":"20","author":"Handzlik","year":"2012","journal-title":"Bioorganic Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejmech.2014.01.065","article-title":"SAR-studies on the importance of aromatic ring topologies in search for selective 5-HT(7) receptor ligands among phenylpiperazine hydantoin derivatives","volume":"78","author":"Handzlik","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1021\/jm010821u","article-title":"Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward alpha(1)- and alpha(2)-adrenoceptors","volume":"44","author":"Barbaro","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Witek, K., Latacz, G., Kaczor, A., Czekajewska, J., \u017bes\u0142awska, E., Chudzik, A., Karczewska, E., Nitek, W., Kie\u0107-Kononowicz, K., and Handzlik, J. (2020). Phenylpiperazine 5,5-Dimethylhydantoin Derivatives as First Synthetic Inhibitors of Msr(A) Efflux Pump in Staphylococcus epidermidis. Molecules, 25.","DOI":"10.3390\/molecules25173788"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1107\/S2052520616003954","article-title":"The Cambridge Structural Database","volume":"72","author":"Groom","year":"2016","journal-title":"Acta Cryst. B"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0922-4106(95)90195-7","article-title":"Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy","volume":"288","author":"Foglar","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1254\/jjp.79.447","article-title":"Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors","volume":"79","author":"Takei","year":"1999","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bmc.2012.11.014","article-title":"Synthesis and preliminary evaluation of pharmacological properties of some piperazine derivatives of xanthone","volume":"21","author":"Szkaradek","year":"2013","journal-title":"Bioorganic Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1016\/j.bmc.2015.09.005","article-title":"Cardiovascular activity of the chiral xanthone derivatives","volume":"23","author":"Szkaradek","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2174\/0929867023369961","article-title":"Arylpiperazines with affinity toward alpha(1)-adrenergic receptors","volume":"9","author":"Manetti","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1016\/j.bmc.2005.12.009","article-title":"Synthesis of new piperazine-pyridazinone derivatives and their binding affinity toward alpha1-, alpha2-adrenergic and 5-HT1A serotoninergic receptors","volume":"14","author":"Betti","year":"2006","journal-title":"Bioorganic Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0002-8703(91)90865-F","article-title":"A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension","volume":"121","author":"Fukiyama","year":"1991","journal-title":"Am. Heart J."},{"key":"ref_59","first-page":"52","article-title":"A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group","volume":"Suppl 1","author":"Joglekar","year":"1998","journal-title":"J. Assoc. Physicians India"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1107\/S1600576715001132","article-title":"Crystal structure determination and refinement via SIR2014","volume":"48","author":"Burla","year":"2015","journal-title":"J. Appl. Cryst."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Cryst. C"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1107\/S1600576719014092","article-title":"Mercury 4.0: From Visualization to Analysis, Design and Prediction","volume":"53","author":"Macrae","year":"2020","journal-title":"J. Appl. Cryst."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"ref_64","unstructured":"LigPrep (2019). Schr\u00f6dinger Release 2019-4, Schr\u00f6dinger LLC."},{"key":"ref_65","unstructured":"(2019). Schr\u00f6dinger Release 2019-4: Glide, Schr\u00f6dinger LLC."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"D440","DOI":"10.1093\/nar\/gkx1109","article-title":"GPCRdb in 2018: Adding GPCR structure models and ligands","volume":"46","author":"Munk","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"Sali","year":"1993","journal-title":"J. Mol. Biol."},{"key":"ref_68","unstructured":"(The PyMOL Molecular Graphics System, 2019). The PyMOL Molecular Graphics System, Version 2.3.2."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16609\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:27:07Z","timestamp":1760131627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":68,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316609"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316609","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}